Previous research has shown that the GTPase activator RGS1 in tumor-specific circulating T cells suppresses chemokine receptor signaling, reducing T cell motility and infiltration of CTL and Th1 cells in mouse models, breast cancer, and lung cancer (59). Here, RGS1 is linked to neoplasm.